Consensus guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide treatments

3

4 David Cheerie^{*1,2}, Margaret Meserve³, Danique Beijer^{4,5}, Charu Kaiwar⁶, Logan Newton^{1,2}, Ana Lisa Taylor Tavares^{7,8}, Aubrie Soucy Verran³, Emma Sherrill³, Stefanie Leonard⁹, Stephan J. 5 6 Sanders^{10,11,12}, Emily Blake¹³, Nour Elkhateeb^{7,8}, Aastha Gandhi^{1,2}, Nicole S. Y. Liang^{14,15}, Jack T. Morgan¹⁶, Anna Verwillow¹⁷, Jan Verheijen¹⁸, Andrew Giles¹⁹, Sean Williams^{1,2}, Maya Chopra²⁰, 7 Laura Croft²¹, Hormos Salimi Dafsari^{22,23,24}, Alice E. Davidson^{25,26}, Jennifer Friedman^{27,28}, Anne 8 9 Gregor^{29,30}, Bushra Hague¹, Rosan Lechner^{31,32}, Kylie-Ann Montgomery^{33,26}, Mina Ryten^{34,26}, Emil Schober^{22,21}, Gabriele Siegel³⁵, Patricia Sullivan³⁶, Bianca Zardetto¹⁶, Timothy Yu^{3,37}, Matthis 10 Synofzik^{4,5}, Annemieke Aartsma-Rus¹⁶, Gregory Costain^{1,2,14,38}, Marlen C. Lauffer^{*16}, and on 11 12 behalf of the N=1 Collaborative⁹

- 13
- 14 *Corresponding authors
- 15 <u>david.cheerie@sickkids.ca</u>
- 16 <u>m.c.lauffer@lumc.nl</u>
- 17
- 18
- ¹ Program in Genetics & Genome Biology, SickKids Research Institute, Toronto, Ontario, M5G
 0A4, Canada
- 21 ² Department of Molecular Genetics, University of Toronto, Toronto, Ontario, M5S 1A8, Canada
- ³ Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts,
- 23 02115, USA
- ⁴ Division of Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical
- 25 Brain Research and Center of Neurology, University of Tübingen, 72076, Tuebingen, Germany
- ⁵ German Center of Neurodegenerative Diseases (DZNE), 72076 Tübingen Germany
- 27 ⁶ Clinical Molecular Geneticist, Department of Pathology and Laboratory Medicine, Precision
- 28 Diagnostics Laboratory, Children's Hospital Colorado, Aurora, CO 80045, USA
- 29 ⁷ Genomics England, London, E14 5AB, UK
- 30 ⁸ Department of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust,
- 31 Cambridge, Cambridgeshire, CB2 0QQ, UK
- 32 ⁹ N=1 Collaborative, 7 Carole Place, Somerville, MA 02143, USA
- ¹⁰ Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University
- of Oxford, Oxford, OX3 7TY, UK
- ¹¹ Department of Psychiatry and Behavioral Sciences, UCSF Weill Institute for Neurosciences,
 University of California, San Francisco, San Francisco, CA 94158, USA
- 37 ¹² New York Genome Center, New York, NY 10013, USA.
- 38 ¹³ Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota 55902, USA
- 39 ¹⁴ Division of Clinical & Metabolic Genetics, Hospital for Sick Children, Toronto, Ontario, M5G
- 40 1X8, Canada
- ¹⁵ Department of Genetic Counselling, Hospital for Sick Children, Toronto, Ontario, M5G 1X8,
 Canada
- 43 ¹⁶ Dutch Center for RNA Therapeutics, Department of Human Genetics, Leiden University Medical
- 44 Center, Leiden, 2333 ZA, The Netherlands

- 45 ¹⁷ Harvard Medical School, Center for Genomic Medicine, Massachusetts General Hospital, 55
- 46 Fruit St, Boston, MA, 02114, USA
- 47 ¹⁸ Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota 55902, USA
- 48 ¹⁹ Ambry Genetics, 1 Enterprise, Aliso Viejo, CA 92656, US
- ²⁰ Rosamund Stone Zander Translational Neuroscience Center, Department of Neurology, Boston
 Children's Hospital & Harvard Medical School, Boston, MA 02115, USA
- 51 ²¹ Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of
- 52 Health, Queensland University of Technology, Brisbane, QLD 4001, Australia
- ²² Department of Pediatrics and Center for Rare Diseases, Faculty of Medicine and University
 Hospital Cologne, University of Cologne, 50937 Cologne, Germany
- ²³ Max-Planck-Institute for Biology of Ageing and Cologne Excellence Cluster for Ageing associated Diseases, 50931 Cologne, Germany
- ²⁴ Randall Division of Cell and Molecular Biophysics, Muscle Signaling Section, King's College
 London, London WC2R 2LS, UK
- 59 ²⁵ UCL Institute of Ophthalmology, London, EC1V 9EL, UK
- 60 ²⁶ UK Platform for Nucleic Acid Therapies (UpNAT)
- 61 ²⁷ Departments of Neurosciences and Pediatrics, University of California San Diego, San Diego,
- 62 California, CA 92093, USA.
- ²⁸ Division of Neurology, Rady Children's Hospital; Rady Children's Institute for Genomic
 Medicine, San Diego, California, CA 92123, USA.
- ²⁹ Department of Human Genetics, Inselspital University Hospital Bern, University of Bern, 3010
 Bern, Switzerland.
- ³⁰ Department for Biomedical Research (DBMR), University of Bern, 3010 Bern, Switzerland.
- ³¹ Department of Clinical Genetics; Erasmus MC 3015 CN Rotterdam, The Netherlands
- 69 ³² Center of Expertise for Neurodevelopmental Disorders (ENCORE); Erasmus MC, 3015 CN
- 70 Rotterdam, The Netherlands
- ³³ UCL GOS Institute of Child Health/UCL Queen Square Institute of Neurology, London, WC1N
 1EH, UK
- 73 ³⁴ Dementia Research Institute, University of Cambridge, Cambridge, CB2 0AH, UK
- ³⁵ Institute of Medical Genetics, University of Zurich, 8952 Schlieren, Switzerland
- ³⁶ Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, 2033,
- 76 NSW, Australia
- 77 ³⁷ Harvard Medical School, Boston, MA 02115, USA
- ³⁸ Departments of Paediatrics, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86 97
- 87
- 88
- 89 90

It is made available under a CC-BY 4.0 International license .

91 Abstract

92 Of the around 7,000 known rare diseases worldwide, disease-modifying treatments are available 93 for fewer than 5%, leaving millions of individuals without specialized therapeutic strategies. In 94 recent years, antisense oligonucleotides (ASOs) have shown promise as individualized genetic 95 interventions for rare genetic diseases. However, there is currently no consensus on which 96 disease-causing DNA variants are suitable candidates for this type of genetic therapy.

97 The Patient Identification Working Group of the N=1 Collaborative (N1C), alongside an 98 international group of volunteer assessors, has developed and piloted consensus guidelines for 99 assessing the eligibility of pathogenic variants towards ASO treatments. We herein present the 100 N1C VARIANT (Variant Assessments towards Eligibility for Antisense Oligonucleotide 101 Treatment) guidelines, including the guiding scientific principles and our approach to consensus 102 building. Pathogenic, disease-causing variants can be assessed for the three currently bestestablished ASO treatment approaches: splice correction, exon skipping, and downregulation of 103 104 RNA transcripts. A genetic variant is classified as either "eligible", "likely eligible", "unlikely eligible", or "not eligible" in relation to the different approaches, or "unable to assess". We also 105 106 review key considerations for assessment for upregulation of transcripts from the wildtype allele, 107 an emerging ASO therapeutic strategy. We provide additional tools and training material to enable

108 clinicians and researchers to use these guidelines for their eligibility assessments.

109 With this initial edition of our N1C VARIANT guidelines, we provide the rare genetic disease 110 community with guidance on how to identify suitable candidates for variant-specific ASO-based 111 therepies and the passibility of integrating such assessments into reuting aligned practice

111 therapies and the possibility of integrating such assessments into routine clinical practice.

112

113 Keywords

114 Antisense oligonucleotides, rare genetic diseases, consensus guidelines, individualized genetic

- 115 therapies, personalized medicine
- 116

117 Introduction

118 There are about 7,000 different rare diseases known to date, with disease-modifying treatments approved for about 5% of them.^{1, 2} A rare disease is defined as a condition that affects less than 119 120 200,000 people in the US, or less than 1 in 2,000 individuals within Europe and Canada.¹ It is 121 estimated that 6% of the world's population lives with a rare disease.³ The majority of rare 122 diseases are thought to be genetic in origin, and with the massive improvements made in genetic 123 diagnostics in the last decades, we can now diagnose up to 50% of individuals who suffer from a rare disease.⁴ As more individuals receive a molecular genetic diagnosis, the need to develop 124 125 targeted treatments is increasingly urgent. Yet, with many of these rare diseases only affecting a 126 handful of individuals across the globe, the usual drug development route is not a viable pathway 127 in most cases and more bespoke therapeutic strategies are necessary.⁵

128 Antisense oligonucleotides (ASOs) are one promising form of genetic therapy. Over 20 different oligonucleotide therapies for general applications have been approved by either the Food and 129 130 Drug Administration (FDA), European Medicines Agency (EMA), the UK's Medicines & Healthcare 131 products Regulatory Agency (MHRA) and/or the Japanese Ministry of Health, Labour and 132 Welfare⁶ and these drugs have been administered and well-studied in thousands of patients worldwide. Systemic delivery is possible (for instance, via subcutaneous or intravenous injection) 133 134 but localized or targeted delivery is also feasible for a growing number of target organs (brain and spinal cord via intrathecal injection, eye via intraocular injection, liver, and muscle via GalNAc and 135

It is made available under a CC-BY 4.0 International license .

transferrin receptor targeting respectively), allowing relatively low doses to be administered with potentially high treatment effects.⁷ Due to the finite half-life of ASOs, treatment needs to be administered repeatedly (often every 1-4 months), but this also allows treatment regimen and dosing to be tailored for each individual where helpful, optimizing to individual benefit and side effects.

Since 2018, multiple groups and organizations have developed ASO treatments for individuals and small groups of patients, either targeted to their specific variant, a single nucleotide polymorphism, or the disease gene in general.⁸⁻¹⁰ These developments have given hope to the rare disease community that individualized, disease-modifying therapies may be a realistic option for additional patients in the near future. More than 10 individuals have received individualized ASO therapies, and more are under development (personal communication).

147 ASOs are versatile in their usage, as they can be employed to: (i) downregulate transcripts in the 148 case of toxic gain-of-function (GoF) and dominant negative variants, (ii) restore the reading frame 149 in case of truncating variants leading to a loss-of-function (LoF) effect, (iii) correct aberrant 150 splicing, and (iv) increase protein expression of the wildtype allele in disorders associated with 151 haploinsufficiency (see Suppl. File 1).¹¹ Yet, not all genetic variants can be targeted with ASOs 152 and even the ones that can be targeted can be distinguished into more eligible (stronger) and less 153 eligible (weaker) candidates. It is thus important to systematically assess every case for its eligibility for ASO treatment to identify the individuals most likely to benefit from such therapies. 154

155 The N=1 Collaborative (N1C) (https://www.n1collaborative.org/) is a global initiative to 156 standardize ultra-rare "n-of-1/few" therapy development and deliver it safely and equitably to 157 individuals with rare diseases. The N1C Patient Identification Working Group (PIWG) is focused 158 on three key areas: (i) identifying suitable genetic variants for ASO development, (ii) determining 159 diseases that are prime candidates for genetic therapy, and (iii) selecting patients who are suitable 160 for individualized genetic therapy development. Additionally, the group aims to provide structured 161 informational support to clinicians, researchers, and patient organizations on identifying 162 individuals most likely to benefit from genetic therapies, understanding the necessary disease 163 information to inform therapeutic decisions, and providing guidance on patient communication 164 throughout the development process. The PIWG has developed criteria and established a 165 consensus on how to assess diagnostic DNA variants for amenability to ASO therapies. The 166 guidelines are based on two recently published frameworks from members within the group^{9,12}, 167 and this work has now been extended beyond the initial frameworks to include criteria for many types of genetic pathological mechanisms causing a monogenic disorder. 168

Here, we describe the development of the consensus guidelines - named N1C VARIANT (Variant
Assessments towards Eligibility for Antisense Oligonucleotide Treatment) guidelines -, present
the first version of the guidelines for use by the wider community, and provide training material
such as example assessments and training videos. We further introduce the "N1C Variant
Eligibility Calculator" that aids with the assessments.

- 174
- 175
- 176
- 177

It is made available under a CC-BY 4.0 International license .

178 Methods

179 **Overview of Guideline Development**

The development of the consensus guidelines (N1C VARIANT Guidelines) was a multisite effort with input from pre-clinical and clinical researchers, and genetics healthcare providers. The guidelines were developed through alternating rounds of revisions and piloting, leading to the final version 1.0 (Suppl. File 1).

- 184
- 185 <u>Version 0.1</u>

Development began with a PIWG internal assessment of sample variants. A single assessor from four participating sites [the Dutch Center for RNA Therapeutics (DCRT), The Netherlands; Hospital for Sick Children (SickKids), Toronto, Canada; the Hertie-Institute for Clinical Brain Research, Tübingen, Germany; Boston Children's Hospital, USA] independently assessed 30 selected variants (previously assessed at the DCRT). The assessment approaches and outcomes from each site were compared, debated by the PIWG, and distilled into an outline of the guidelines.

193

194 This outline of the guidelines for ASO eligibility proposed the purpose, content, format, and 195 definitions of classifications. The outline was shared with the PIWG membership for input and 196 revised based on their feedback. This outline was used to draft the first version of the consensus 197 guidelines (version 0.1). This first version was only applicable to LoF variants in genes causing 198 autosomal recessive and X-linked recessive disorders, and only assessed variants for exon 199 skipping and splice correcting ASOs. This draft was shared with the PIWG, where feedback was 200 collected and applied. Following revisions by the PIWG, the revised draft was shared with a group 201 of external volunteers (n=5), who reviewed the guidelines, provided feedback, and assessed a 202 test set of three variants (Suppl. File 2).

- 203
- 204 <u>Version 0.2</u>

Feedback and assessment results from the external volunteers were collected as written responses and used for further revision (version 0.2). We paid attention not only to the feedback on the guidelines but also to how the test variants were assessed and whether the reasoning for the assessments was in alignment with our guidelines. When assessors did not come to the correct conclusion we rephrased and adjusted the guidelines to aid with the assessments.

210

Version 0.2 was once again shared with the PIWG for edits and feedback before being distributed to a larger group of external volunteer assessors (n=14) for a second round of piloting on a set of twelve test variants (Suppl. File 2). Once again, feedback and assessment reports were collected and used to revise the guidelines.

215 216 Version 0.3

In version 0.3, the guidelines were expanded to include assessment of eligibility towards
 ASO/siRNA-mediated transcript knockdown for GoF and dominant negative variants, and towards
 upregulation from the WT allele (e.g., targeted augmentation of nuclear gene output [TANGO]¹³)
 as well as all known types of inheritance patterns. This revised guideline was shared with external
 volunteers (n=19) for a third round of piloting with 15 test variants (Suppl. File 2). Assessment

results and feedback were collected as written responses, in addition to the explanations of their

It is made available under a CC-BY 4.0 International license .

assessments, and together used by the PIWG to refine the guidelines. This final version (version
1.0) was shared with all co-authors for final feedback before submission.

225

226 Test Variant Curation

227 All test variants were selected by one member of the PIWG who did not participate in the 228 assessment rounds. Selected variants were sourced from published literature or the ClinVar 229 database (https://www.ncbi.nlm.nih.gov/clinvar/). Two PIWG members independently assessed 230 each variant and determined the feasibility of the variant assessment depending on the publicly 231 available information (including prior success with ASO development, where applicable). Once a variant's analysis and classification were agreed upon, these members drafted a "correct answer" 232 233 representing the expected outcome using the guidelines (Suppl. File 3). Answers with 234 explanations were communicated to all volunteer assessors after each assessment round.

235

236 Guidelines Piloting

Volunteer assessors ranged from graduate students (at both the Masters and PhD level) to faculty
with different levels of experience in clinical genetics and ASO therapy development. Assessors
included trained basic science or translational researchers, genetic counselors, and clinicians.
Assessors were recruited via the professional networks connected to the N1C (e.g., departmental
colleagues, announcements in the N1C newsletter, and international conferences featuring N1C
PIWG members). An overview of where the assessors are currently working and what their role
is given in Table 1.

244

Country of Institution	Number of Assessors	Institutions	Role/Position	
Australia	2	Children's Cancer Institute	PhD candidate	
		Queensland University of Technology	Senior Scientist	
Canada	4	The Hospital for Sick Children Masters research students (3) Genetic Counselo		
Germany	many 3 Hertie Institute for Clinical Br Research		Postdoctoral Research Fellow	
		University of Cologne	Clinician Scientist MD candidate	
The Netherlands	erlands 2 Dutch Center for RNA Therapeutics, LUMC		PhD candidate	
		Erasmus Medical Center	MD/PhD candidate	
Switzerland	2	University Hospital of Bern	Senior Scientist	

Table 1: Global makeup of volunteer assessors including current institution and role/position.

It is made available under a CC-BY 4.0 International license .

		University of Zurich	Senior Scientist
United Kingdom	4	University College London	Associate Professor Professor of Neuroscience and Clinical Geneticist Research Associate
		Genomics England	Clinical Fellow
United States	8	Boston Children's Hospital	Genetic Counselor Clinician Scientist
		Mayo Clinic	Research Fellow Senior Bioinformatician
		Ambry Genetics	Genetic Counselor
		Massachusetts General Hospital	Genetic Counselor
		Rady Children's Hospital	Clinician Scientist
		Children's Hospital Colorado	Clinical Molecular Geneticist

246

Once the assessors agreed to participate, they received a welcome email with an introduction tothe assessments and initial information on the timeline and tasks.

249

250 Video Example Development

To support the assessor, exemplary assessments of selected test set variants were provided via short videos. The video examples provide step-by-step instructions on assessing variants using the N1C VARIANT guidelines. Videos were designed and recorded on Microsoft PowerPoint. Videos were reviewed by both the PIWG and the volunteer assessors. A subset of videos was first shared with the PIWG, who provided feedback on the content and structure. Videos were then revised before being shared with volunteer assessors during each round of piloting. Feedback on the videos was collected as written responses.

258

259 The variants discussed in the video examples were selected by members of the PIWG. The 260 variants were assessed using the N1C VARIANT guidelines. All selected variants were sourced 261 from published literature or the ClinVar database, with some already having a developed ASO. 262 Two members of the PIWG compared analyses and determined the feasibility of the variant 263 assessment approach. Once a variant's analysis and classification were agreed upon, a step-by-264 step analysis was recorded - representing a suggested analysis approach to be taken by 265 assessors using the N1C VARIANT guidelines, along with the expected classification of the 266 variant. Videos are available on the N=1 Collaborative YouTube page

- 267 (https://www.youtube.com/playlist?list=PL1FIwS0tbJHj0-aDMmZ5fUy5d40eiwa8B) and N1C
- 268 website (https://www.n1collaborative.org/post/n1c-variant-guidelines).
- 269

270 Development of the N1C Variant Eligibility Calculator

Based on feedback from the assessors and members of the N1C PIWG, an interactive decision

- tree was developed to facilitate applying the guidelines (the N1C Variant Eligibility Calculator).
- 273 First, a catalog with questions and answers based on the guidelines was written, including
- 274 indications of connections between different sections. For the development of an interactive online
- tool, HTML and Javascript code was written based on the catalog of questions with the help of
- 276 ChatGPT which provided a skeleton of the code upon request. The tool was deployed on the N1C
- website (http://eligibilitycalculator.n1collaborative.org/). The full code is available on the N1C'sGitHub page:
- 279 https://github.com/N1Collaborative/Variant-Eligibility-Calculator. The eligibility calculator was
- thoroughly tested by several co-authors of this manuscript, including one assessor doing their
- assessments of the final 15 variants using the tool to see if they came up with the correct answers.
- 282 Feedback was gathered through a written response and incorporated accordingly.
- 283

284 Upregulation from the WT allele Table

285 Our guidelines refer to various resources for the assessment of pathogenic variants towards upregulation from the WT allele (Suppl. File 1), including four landmark papers¹³⁻¹⁶. To aid in the 286 287 assessment of variants toward upregulation eligibility, a combined file containing the findings from 288 each suggested paper was generated (Suppl. File 4). The data from Mittal et al., Lim et al., and 289 Felker et al., was extracted from the papers' supplementary files. The data from Liu et al. was 290 extracted from the uORF website (http://rnainformatics.org.cn/RiboUORF/) through POST 291 requests. All data from all available genes from each paper was combined into one Excel file. For 292 each gene on the combined file, pLI scores and ClinGen haploinsufficiency (HI) scores were 293 from indicated. The pLI score was downloaded gnomAD v4.0 294 (https://gnomad.broadinstitute.org/downloads). ClinGen HI scores were downloaded from 295 ClinGen (https://search.clinicalgenome.org/kb/downloads).

297 Results

298 **Purpose of guidelines**

We have developed a consensus guideline (N1C VARIANT guideline) for eligibility assessment and prioritization of pathogenic variants to ASO treatments. With these guidelines, assessors can identify genetic variants most likely to benefit from an ASO-based therapy and distinguish these variants from currently less suitable candidates. The full guidelines are available in Supplementary File 1. Updated versions of the guidelines will also be available via the N1C website (https://www.n1collaborative.org/post/n1c-variant-guidelines).

305

296

The guidelines take into consideration the genetic diagnosis of the individual, molecular principles, and pathomechanism of the disease and genetic variant. The purpose of the guideline is to provide clinicians, geneticists, and researchers with a framework for analyzing and classifying disease-causing variants for their amenability to ASO-based therapy. With these guidelines, assessors should be able to:

Identify variants eligible for assessment and use publicly available databases and
 resources to assist in the variant assessment process

- Assess whether a variant is eligible for ASO-mediated splice correction (i.e., correction of
 mis-splicing)
- 315 3. Assess whether a variant is eligible for ASO-mediated exon skipping
- 4. Assess whether a candidate gene and/or variant is eligible for siRNA or ASO-mediated
 transcript knockdown
- 5. Classify variants as either "eligible", "likely eligible", "unlikely eligible", "not eligible" for the
 aforementioned ASO approaches, or as "unable to assess" using these guidelines. The
 definition of each classification is dependent on the type of ASO therapy
- 321 6. Consider strategies for the upregulation of wildtype alleles in cases of haploinsufficiency322

323 Overall, these guidelines focus on evaluating (likely) pathogenic, disease-causing variants for 324 eligibility towards ASO treatment. For a full assessment of a patient case, disease and individual-325 specific clinical factors have to also be taken into consideration, but this work is beyond the scope 326 of these guidelines. These guidelines reflect a general way of evaluating variants, but there are 327 many gene, mechanism, and disease-specific considerations and/or exceptions. Throughout the 328 guidelines, relevant exceptions of variant assessments are indicated.

329

330 Guideline Structure

331 Only a subset of the guidelines will be relevant to evaluating any one specific variant. The 332 guidelines walk readers through a series of steps where they are prompted to verify variant 333 annotations, inheritance patterns, and pathomechanisms. If critical information is unavailable or 334 insufficient, the guidelines prompt readers that this variant is ineligible for further assessment 335 ("unable to assess"). Conversely, if the necessary information is available and known, readers 336 can use the guidelines to identify appropriate or multiple applicable ASO strategies: splice 337 correction, canonical exon skipping, RNA knockdown, or upregulation from the WT allele. Upon 338 identification of a relevant ASO strategy, readers can direct themselves to the relevant section 339 with the help of flowcharts where they assess the variant's eligibility towards a specific strategy in 340 greater detail. Throughout the guideline, relevant publicly available resources to aid with the 341 assessments are shared.

342

As part of the guidelines, assessors are encouraged to check whether an ASO has already been developed for a specific variant, exon, or disorder (whether in clinical or preclinical stages). Clear criteria are provided to define what constitutes sufficient evidence for a functional ASO, depending on the strategy. To assist in this search, the guidelines offer resources and recommended search terms for identifying functionally tested ASOs.

348

349 At the end of the assessment, assessors can classify a variant's eligibility towards splice 350 correction, canonical exon skipping, and/or RNA knockdown based on the information gathered 351 using the guidelines. The classification criteria were developed as part of the consenting process 352 and are outlined below. Assessment strategies are provided for upregulation from the WT allele, 353 but classifications towards eligibility are not defined because this area of ASO therapeutics is less 354 established to date. Instead, the guidelines provide context on when upregulation from the WT 355 allele might be used, and considerations for their development. We further provide an easy way 356 to check for multiple approaches at once by combining available resources on upregulation from 357 the WT allele into one simple Excel table (Suppl. File 4).

358

It is made available under a CC-BY 4.0 International license .

359 Classification terms

The complexity of the assessments necessitated defining new terms for a classification schema. Prior published classification schema assessed variant amenability to ASO therapy using terms such as "probably", "possibly", "unlikely" amenable, "exclude from assessment," and "consider for exon skipping".^{9,12} However, these schemas focused on only certain types of variants and ASO strategies. To improve on these prior schemas and expand them to multiple ASO strategies, version 1.0 of these guidelines now employs five tiers for all classifications: "eligible", "likely eligible", "unlikely eligible", "not eligible", and "unable to assess".

367

"Eligible" variants are those for which functional evidence supports the effectiveness of an ASO 368 369 approach. For splice-correcting ASOs, this means that an ASO has already been developed and 370 shown to be effective, either clinically or pre-clinically, for the specific splice-altering variant. In 371 the context of exon skipping, which aims to "skip" the exon containing the pathogenic variant to 372 produce a truncated yet functional protein product, one would search for functional evidence of 373 exon skipping being non-pathogenic. This would include experimentally induced exon skipping 374 events (i.e., CRISPR deletions, ASOs) showing functional evidence at the protein level that 375 residual protein function remains. This also includes naturally occurring exon skipping events (i.e., 376 benign exon skipping events found in healthy populations). A pathogenic variant found within an 377 exon where either experimentally induced or naturally occurring exon skipping occurs would then 378 be classified as eligible for canonical exon skipping ASOs. Similar ideas apply when assessing 379 variants for eligibility towards knockdown. If a gain-of-function or dominant negative variant, both 380 of which can be considered for knockdown, is found on a gene where a non-allele or non-variant 381 specific knockdown approach has been functionally proven, the variant can be classified as 382 eligible towards knockdown ASOs.

383

384 "Not eligible" variants are those for which a specific ASO therapeutic approach is not considered 385 possible. This may be due to functional evidence demonstrating the failure of ASO therapies, for 386 example, canonical exon skipping led to a non-functional protein, or molecular criteria that render 387 the variant unsuitable for ASO targeting. Examples of "not eligible" variants include single-exon 388 genes in the context of exon skipping ASOs or genes with tightly regulated dosage in RNA 389 knockdown strategies.

390

391 "Likely eligible" variants are those that, based on molecular criteria, could potentially be targeted
392 by an ASO, although no functional evidence is currently available to confirm this. Conversely,
393 "unlikely eligible" variants are those where molecular criteria suggest an ASO is unlikely to be
394 effective, but no functional evidence directly contradicts the potential use of an ASO.

395

Variants are classified "unable to assess" when they either do not apply to these guidelines, e.g.
are of a type that cannot be assessed, or if there is not enough information available that allows
for an assessment of the variant, e.g., the inheritance pattern of the variant is unknown or no
information on the pathomechanism is available.

400

401 Videos

402 At the time of publication, 12 videos have been created and shared (Table 2). These videos 403 provide step-by-step guidance for assessors, highlighting key resources and assessment 404 techniques. Each video demonstrates the assessment of a specific variant towards a relevant

It is made available under a CC-BY 4.0 International license .

- 405 strategy, with each example leading to a unique outcome. The videos can be found on the N1C
- 406 YouTube channel
- 407 (https://www.youtube.com/playlist?list=PL1FIwS0tbJHj0-aDMmZ5fUy5d40eiwa8B) and via the
- 408 N1C website (https://www.n1collaborative.org/post/n1c-variant-guidelines).
- 409

410 **Table 2:** List of video examples referred to and published with version 1.0 of the N1C VARIANT

411 guidelines. Variants normalized using Mutalyzer (https://mutalyzer.nl/).

Video	Variant	Gene Symbol	ASO Strategy	Outcome/Class ification
1	NM_000350.3:c.2626C>T, p.(Gln876*)	ABCA4	Canonical exon skipping	Eligible
2	NM_016589.4:c.597-1340A>G	TIMMDC1	Splice correcting	Eligible
3	NM_000533.5:c.680dup, p.(Cys228Leufs*5)	PLP1	Canonical exon skipping	Not eligible
4	NM_003793.4:c.213+1G>C	CTSF	Splice correcting	Not eligible
5	NM_000277.3:c.611A>G, p.(Tyr204Cys)	PAH	Splice correcting	Unlikely eligible
6	NM_025152.3:c.815-27T>C	NUBPL	Splice correcting	Unlikely eligible
7	NM_024312.5:c.3503_3504del, p.(Leu1168GInfs*5)	GNPTAB	Canonical exon skipping	Unlikely eligible
8	NM_001040142.2:c.5645G>A, p.(Arg1882Gln)	SCN2A	Knockdown	Eligible
9	NM_001165963.4:c.3733C>T, p.(Arg1245*)	SCN1A	Upregulation from the WT allele	Eligible
	NM_130839.5:c.67C>T, p.(Arg23*)	UBE3A		
10	NM_003793.4:c.264del, p.(Cys89Alafs*59)	CTSF	Canonical exon skipping	Likely eligible
11	NM_000170.3:c.538C>T, p.(Gln180*)	GLDC	Canonical exon skipping	Not eligible
12	Multiple variants		N/A	Unable to assess

412

413

414

415 Variant Eligibility Calculator

416 To support the assessment and help assessors focus on going through the sections of the 417 guidelines relevant to their current assessment, the N1C Variant Eligibility Calculator was 418 developed. At the time of publication, the eligibility calculator walks assessors step-by-step 419 through version 1.0 of the N1C VARIANT guidelines. One key feature of the calculator is the 420 inability to skip question prompts. Each step discussed in the guidelines is crucial for in-depth 421 variant assessment and is required for accurate variant classification. Due to the inability to 422 progress without answering the question, users of the calculator are encouraged to further 423 research the gene or variant before proceeding with the assessment. Additionally, the calculator 424 takes into consideration the kind of variants (i.e., missense, stop gain, synonymous) before 425 directing users to relevant sections of the guidelines. Overall, this tool allows users to 426 systematically navigate the guidelines, acting as a "checklist" before proceeding with assessments. The calculator further provides users with the ability to track their assessments and 427 428 receive a printout of the specific questions answered and what the answers were to understand 429 the overall classification and identify potential mistakes during the assessment process. The 430 calculator is available via the N1C website (http://eligibilitycalculator.n1collaborative.org/) and the 431 N1C's GitHub page (https://n1collaborative.github.io/Variant-Eligibility-Calculator/).

432 433

434 Discussion

Here we introduced version 1.0 of the N1C VARIANT (Variant Assessments towards Eligibility
for Antisense Oligonucleotide Treatment) guidelines for the assessment of pathogenic variants
for eligibility towards ASO treatments, alongside the process of their development and consenting.
Additionally, we introduce and discuss the development of training materials and tools to aid with
variant assessments.

440

These guidelines represent the first proposed international consensus approach for evaluating the potential eligibility of pathogenic variants causing monogenic disorders toward ASO therapies. With the significant progress and publicity in the last few years regarding the development of individualized genetic therapies⁸⁻¹⁰ there is hope within the rare disease community that ASOs may benefit an increasing number of community members. With our guidelines and the accompanying training materials and tools, we aim to support the rare disease community by providing guidance on which variants are most likely to be eligible for ASO therapies.

448

As a takeaway from the iterative process of developing these guidelines, we want to emphasize that this is a complex assessment procedure that takes time to learn. Similar to the annotation and classification of pathogenicity for genetic variants with the ACMG guidelines¹⁷, the assessment of pathogenic variants for their eligibility for ASO treatments takes many different aspects into account.

454

We propose a new five-tier classification schema for ASO treatment amenability, whereby a variant is classified with respect to specific ASO strategies and can thus receive different labels for different types of ASO treatments. The classifications are "eligible", "likely eligible", "unlikely eligible", "not eligible", or "unable to assess". While the "eligible" and "not eligible" definitions are clear, categorizing and classifying variants as "likely eligible" and "unlikely eligible" proves to be more challenging, as the evidence for or against eligibility exists on a spectrum. Future work will

461 aim to refine these categories further, mirroring the efforts to introduce more gradations into the 462 ACMG/AMP variant classification scheme.

463 We further expect to communicate adjustments in the upcoming years, as technologies advance 464 and knowledge grows regarding which genetic variants are most likely amenable to an ASO 465 treatment. We expect that in some cases variant classifications for a certain ASO approach will 466 change with these adjustments, for example, due to new information on the feasibility of ASO 467 designs for certain types of variants, necessitating reassessments over time. In that regard, we 468 would like to point out that it is important to read the literature on available ASO treatments 469 critically and scrutinize the methodology used and the functional data provided, before 470 considering a variant eligible for ASO treatments.

471

472 At this point, there is a limited number of ASOs developed and clinically tested, thus not for all 473 different variant types, pathomechanisms, and inheritance patterns discussed herein are ASOs 474 currently available. That means that no gold-standard evidence for many considerations were 475 available for the establishment of these guidelines, and these guidelines can thus be considered 476 expert opinions. However, the guidelines were based on the collective expertise gained from 477 assessing about 1.500 variants since 2018 at the sites of the PIWG members (BCH. SickKids. 478 DCRT), and the knowledge the PIWG members have on ASO design and development, which 479 involves leading experts in the field of ASO development and tailored ASO therapies.

480

While efforts were made to test the guidelines with various assessors from different professional
backgrounds, the application of these guidelines in diverse healthcare settings might reveal
additional needs for adjustments and refinements in the future.

484

Although the amenability of a specific variant to a certain ASO therapeutic strategy is a fundamental first step, disease- and patient-specific factors are equally important considerations in the development and provision of individualized genetic therapies.¹¹ Considerations will also include the reversibility and severity of symptoms. This means that an eligible variant does not necessarily equal an eligible patient. The assessments of disease- and patient-specific factors are outside the scope of this work and will require additional recommendations and guidelines.^{18,19}

492 Ideally, we would like to see the integration of the eligibility assessments into clinical practice, to 493 not only provide individuals suffering from rare diseases with a diagnosis but also with information 494 on possible treatment approaches, where applicable. We believe that with the additional training 495 material and test variants provided, clinical geneticists and specialist human geneticists working 496 in laboratories and diagnostic centers can train themselves to become assessors. In the long 497 term, we envision automation of our guidelines and assessment procedures in the form of tools 498 that take the pathogenic variant as input and deliver an analysis of the best therapeutic strategy 499 for each individual.

500

501 We plan to regularly update the guidelines as well as the tools and training material. Updated 502 versions with the version number and date of the update will be provided on the N1C website 503 (https://www.n1collaborative.org/post/n1c-variant-guidelines).

- 504
- 505
- 506

507 Appendices

- 508 Supplement material
- 509 Supplementary File 1 Version 1.0 of the guidelines
- 510 Supplementary File 2 Overview of all test variants for the three rounds
- 511 Supplementary File 3 Answer keys for all test variants in the three rounds
- 512 Supplementary File 4 Upregulation from the WT allele Summary Table
- 513

514 **Declaration of interests**

- 515 Nothing to declare.
- 516

517 Acknowledgments

518 We would like to thank further N1C members for their input and help during the development of 519 these guidelines. We especially want to thank Nicole Nolen for all her help and support in making 520 the training material and tools available on the N1C website. We also thank all families and 521 clinicians who have provided us with their genetic diagnoses over the years, which ultimately led 522 to the establishment of these guidelines.

523 This work was supported by the European Union, project European Rare Disease Research 524 Alliance (ERDERA, # 101156595) (to M.S. and A.A.-R.). D.C. is supported by a SickKids 525 Restracomp Master's Scholarship and the SickKids Innovators Fund. L.N. is supported by a 526 Canada Graduate Scholarship - Master's from the Canadian Institutes of Health Research 527 (CIHR). D.C., B.H., and G.C. also acknowledge support from CIHR (PJT186240). D.B. is 528 supported by a Humboldt Research Fellowship and the Hertie-Network of Excellence in Clinical 529 Neuroscience. M.C.L is funded by a Walter Benjamin Fellowship from the DFG. A.E.D. K.-A.M. 530 and M.R. are supported by the UK Platform for Nucleic Acid Therapies (UpNAT). B.Z., A.A.-R., 531 R.L. are supported by a ZonMW PSIDER grant.

532

533 Author contributions

534 D.C. and M.C.L. of the N1C PIWG conceptualized the N1C VARIANT guidelines. D.C. and M.C.L. 535 drafted the guidelines and the manuscript, conducted the assessment rounds, and evaluated and 536 implemented the feedback. D.C. made the example videos. M.C.L. selected the test variants for 537 assessment and developed and built the variant eligibility calculator.

538 M.M., D.B., C.K., L.N., A.L.T.T., A.S., E.S., L.N., S.S., M.S., T.Y., A.A.-R., G.C. are members of 539 the N1C PIWG; they reviewed the outlines and drafts of the different rounds of guidelines and

edited the manuscript. They further provided feedback on the videos. M.M., D.B., C.K., and L.N.,

also participated in the variant assessment training and provided feedback and explanations on

the assessments. S.L. facilitated the PIWG meetings, set up documents, and helped with putting the work onto the public databases and the N1C website.

- E.B., N.E., A.G., N.L., J.M., A.V., J.V., A.G., S.W., M.C., L.C., H.S.D., A.E.D., J.F., A.G., R.L., K.A.M., M.R., E.S., G.S., P.S. participated as assessors and provided feedback on the guidelines
 and training material. B.H. made the upregulation from the WT table. L.N. and B.Z. tested the
 variant eligibility calculator and provided feedback.
- 548 Authors were listed as follows: Junior members of the N1C PIWG were named first, followed by
- 549 assessors who participated in multiple rounds of assessments and provided extensive feedback,
- all other assessors were named in alphabetical order. Lastly, senior members of the N1C PIWG
- 551 were named. D.C. and M.C.L. of the N1C PIWG were placed as first and senior authors 552 respectively as they were leading the overall effort.

553 Web Resources

- 554 Videos available on YouTube: https://www.youtube.com/playlist?list=PL1FlwS0tbJHj0-
- 555 aDMmZ5fUy5d40eiwa8B
- 556
- 557 Calculator available on GitHub and N1C website:
- 558 https://n1collaborative.github.io/Variant-Eligibility-Calculator/
- 559 and http://eligibilitycalculator.n1collaborative.org/
- 560
- 561 Guidelines available on N1C website: https://www.n1collaborative.org/post/n1c-variant-
- 562 guidelines
- 563

564 Data and Code Availability

565 Data is available in supplementary files 2, 3, and 4 for variant assessments and upregulation from 566 the WT allele approaches. All code was deployed on GitHub under an open-source AGPL license 567 (https://github.com/N1Collaborative/Variant-Eligibility-Calculator).

568

569

570 References

- 571
- 1. Haendel, M., Vasilevsky, N., Unni, D., Bologa, C., Harris, N., Rehm, H., Hamosh, A.,
- 573 Baynam, G., Groza, T., McMurry, J. et al. (2020). How many rare diseases are there? Nat. Rev. 574 Drug Discov. 19, 77–78.
- 575 2. Kaufmann, P., Pariser, A.R., Austin, C. (2018). From scientific discovery to treatments for
- 576 rare diseases the view from the National Center for Advancing Translational Sciences Office
 577 of Rare Diseases Research. Orphanet Journal of Rare Diseases 13, 196.
- 578 3. Ferreira, C.R. (2019). The burden of rare diseases. Am. J. Med. Genet. 179, 885–892.
- 4. Nurchis, M.C., Altamura, G., Riccardi, M.T., Radio, F.C., Chillemi, G., Bertini, E.S., Garlasco,
- 580 J., Tartaglia, M., Dallapiccola, B., Damiani, G. (2023). Whole genome sequencing diagnostic 581 yield for paediatric patients with suspected genetic disorders: systematic review, meta-analysis,
- and GRADE assessment. Archives of Public Health 81, 93.
- 583 5. Aartsma-Rus, A., van Roon-Mom, W., Lauffer, M., Siezen, C., Duijndam, B., Coenen-de Roo,
- T., Schüle, R., Synofzik, M., Graessner, H. (2023). Development of tailored splice-switching
 oligonucleotides for progressive brain disorders in Europe: development, regulation, and
 implementation considerations. RNA 29, 446–454.
- 587 6. Egli, M., Manoharan, M. (2023). Chemistry, structure and function of approved
- 588 oligonucleotide therapeutics. Nucleic Acids Res. 51, 2529–2573.
- 589 7. Roberts, T.C., Langer, R., Wood, M.J.A. (2020). Advances in oligonucleotide drug delivery.
- 590 Nature Reviews Drug Discovery 19, 673–694.
- 591 8. Kim, J., Hu, C., Moufawad El Achkar, C., Black, L.E., Douville, J., Larson, A., Pendergast,
- M.K., Goldkind, S.F., Lee, E.A., Kuniholm, A. et al. (2019). Patient-Customized Oligonucleotide
 Therapy for a Rare Genetic Disease. N. Engl. J. Med. 381, 1644–1652.
- 594 9. Kim, J., Woo, S., de Gusmao, C.M., Zhao, B., Chin, D.H., DiDonato, R.L., Nguyen, M.A.,
- 595 Nakayama, T., Hu, C.A., Soucy, A. et al. (2023). A framework for individualized splice-switching 596 oligonucleotide therapy. Nature 619, 828–836.
- 10. Ziegler, A., Carroll, J., Bain, J.M., Sands, T.T., Fee, R.J., Uher, D., Kanner, C.H., Montes, J.,
- 598 Glass, S., Douville, J. et al. (2024). Antisense oligonucleotide therapy in an individual with
 - 599 KIF1A-associated neurological disorder. Nat. Med.
 - 600 11. Lauffer, M.C., van Roon-Mom, W., Aartsma-Rus, A., N = 1 Collaborative. (2024).
 - 601 Possibilities and limitations of antisense oligonucleotide therapies for the treatment of
 - 602 monogenic disorders. Commun. Med. (Lond) 4, 6–1.

It is made available under a CC-BY 4.0 International license .

- 603 12. Zardetto, B., Lauffer, M.C., van Roon-Mom, W., Aartsma-Rus, A., on behalf of the N = 1
- 604 Collaborative. (2024). Practical Recommendations for the Selection of Patients for
- 605 Individualized Splice-Switching ASO-Based Treatments. Human Mutation 2024, 9920230.
- 606 13. Lim, K.H., Han, Z., Jeon, H.Y., Kach, J., Jing, E., Weyn-Vanhentenryck, S., Downs, M.,
- 607 Corrionero, A., Oh, R., Scharner, J. et al. (2020). Antisense oligonucleotide modulation of non-
- 608 productive alternative splicing upregulates gene expression. Nature Communications 11, 3501.
- 609 14. Mittal, S., Tang, I., Gleeson, J.G. (2022). Evaluating human mutation databases for
- 610 "treatability" using patient-customized therapy. Med 3, 740–759.
- 611 15. Felker, S.A., Lawlor, J.M.J., Hiatt, S.M., Thompson, M.L., Latner, D.R., Finnila, C.R.,
- 612 Bowling, K.M., Bonnstetter, Z.T., Bonini, K.E., Kelly, N.R. et al. (2023). Poison exon annotations
- 613 improve the yield of clinically relevant variants in genomic diagnostic testing. Genetics in 614 Medicine 25, 100884.
- 16. Liu, Q., Peng, X., Shen, M., Qian, Q., Xing, J., Li, C., Gregory, R.I. (2022). Ribo-uORF: a 615 616 comprehensive data resource of upstream open reading frames (uORFs) based on ribosome 617 profiling. Nucleic Acids Res. 51, D248–D261.
- 618 17. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde,
- 619 M., Lyon, E., Spector, E. et al. (2015). Standards and guidelines for the interpretation of
- 620 sequence variants: a joint consensus recommendation of the American College of Medical
- 621 Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405-622 424.
- 18. Synofzik, M., van Roon-Mom, W.M.C., Marckmann, G., van Duyvenvoorde, H.A., 623
- 624 Graessner, H., Schüle, R., Aartsma-Rus, A. (2022). Preparing n-of-1 Antisense Oligonucleotide 625 Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. Nucleic Acid Ther. 32, 83–94.
- 626
- 627 19. Jonker, A.H., Tataru, E., Graessner, H., Dimmock, D., Jaffe, A., Baynam, G., Davies, J.,
- 628 Mitkus, S., Iliach, O., Horgan, R. et al. (2024). The state-of-the-art of N-of-1 therapies and the 629 IRDiRC N-of-1 development roadmap. Accepted for publication in Nature Reviews Drug
- 630 Discovery.
- 631
- 632